10Jul 2018

PREDICTIVE AND PROGNOSTIC VALUES OF HYPOXIA-INDUCIBLE FACTOR (HIF)-1Α AND TAU-PROTEIN EXPRESSION IN SEROUS OVARIAN CANCER (SOC) PATIENTS TREATED WITH CHEMOTHERAPY.

  • Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
  • Department of medical oncology, Faculty of Medicine, Zagazig, Egypt.
  • Department of Clinical Oncology and nuclear medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
  • Department of Gynecology and obstetrics, Zagazig University Faculty of Medicine, Zagazig, Egypt.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Abstract Background: Serous ovarian carcinoma (SOC) is considered the most common epithelial ovarian malignancies. SOC is still having dismal outcome mainly due to early invasion, spread and resistance to chemotherapeutic agents e.g. platinum based drugs. Recent researches focused on detection of novel therapies and how to overcome chemotherapy resistance in those patients. Hypoxia inducible factor (HIF)-1 ? is the transcription factor which is the first detected mediator of cell response to hypoxia in normal and malignant cells. Tau protein (50–64 kD), which is a gene product that can bind to beta-tubulin. It was isolated from brain tissue and was associated with many neurodegenerative diseases. Aim of the study to clarify the predictive and prognostic roles of (HIF)-1? and Tau protein expression in malignant tissues of 40 patients with SOC received paclitaxel first-line chemotherapy. Methods; we have evaluated expression of HIF-1? and Tau protein expression by using immunohistochemistry in malignant tissues of forty patients of SOC. We evaluated the predictive and prognostic roles of expression of both proteins in SOC patients that have received first-line chemotherapy. We have followed patients for about three years to assess overall survival rate (OS) and resistance to chemotherapy. Results: tissue expression of HIF-1? and Tau-protein in SOC was positively correlated with advanced stage of the tumor (p=0.006& 0.002 respectively), peritoneal implants (p=0.005), higher grade of the tumor(p=0.001& 0.008 respectively), presence of distant metastases (p=0.002& 0.032 respectively), presence of ascites (p=.034& 0.046 respectively) and L.N metastases (p=0.003& <0.001 respectively), chemoresistance (p= 0.03& 0.042 respectively), recurrence of the disease after successive therapy and unfavorable survival rates (p<0.001) Conclusion: both HIF-1? and Tau-protein are markers of unfavorable outcome of SOC patients.

  1. Konstantinopoulos PA and Matulonis UA. Cur?rent status and evolution of preclinical drug development models of epithelial ovarian can?cer. Front Oncol 2013; 3: 296.
  2. Jayson GC, Kohn EC, Kitchener HC and Leder?mann JA. Ovarian cancer. Lancet 2014; 384: 1376-1388.
  3. Ying H, Qu D, Liu C, Ying T, Lv G, Jin SH and XU Chemoresistance is associated with Beclin-1 and PTEN expression in epithelial ovarian cancers ONCOLOGY LETTERS 2015;9: 1759-1763,
  4. Rajanbabu A, Kuriakose S, Ahmad SZ et al. Evolution of surgery in advanced epithelial ovarian cancer in a dedicated gynae?cologic oncology unit-seven year audit from a tertiary care centre in a developing country. E-cancer medical science 2014; 8: 422.
  5. Takebe N, Miele L, Harris PJ et al.Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol 2015; 12: 445-64.
  6. Ramos P and Bentires-Alj M. Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene 2015; 34: 3617-26.
  7. Mabjeesh NJ, Amir S. Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol.2007; 22:559?72.
  8. Wilson KG, Tennant AD, McKeating AJ. Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions. J Hepatol. 2014;61:1397?406.
  9. Rouzier R1,Rajan R,?Wagner P et al.Microtubule-associated protein tau: amarker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 2005, 102:8315?20
  10. Cook, C.; Stankowski, J.N.; Carlomagno, Y et al: A new key to unlock tau?s role in neurodegeneration. Alzheimers Res. Ther. 2014, 6, 29.
  11. Kurman RJ, Carcangiu ML, Herrington CS et al. WHO Classification of Tumors of Female Reproductive Organs. 4th ed.Lyon: International Agency for Research on Cancer. 2014
  12. Prat J . FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014; 124 (1):1-5.
  13. Hsu SM, Raine L and Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J HistochemCytochem. 1981; 29:577-580.
  14. Smoter?M, Bodnar L, Grala B, et al. Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy. J Exp Clin Cancer Res. 2013 Apr 30; 32:25. doi: 10.1186/1756-9966-32-25.
  15. Osman NA, Abd El-Rehim DM and Kamal IM. Defective Beclin-1 and elevated hypoxia-inducible factor (HIF)-1α expression are closely linked to tumorigenesis, differentiation, and progression of hepatocellular carcinoma. Tumour Biol; 2015; 36(6): 4293?4299.
  16. Jie Qin1, Yan Liu2, Yongkui Lu2 et al. Hypoxia-inducible factor 1 alpha promotes cancer stem cells-like properties in human ovarian cancer cells by up regulating SIRT1expression SCieNTifiC REPOrts. 2017
  17. Acs G, Xu X, Chu C et al. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 2004;100:2376?86.
  18. Jin, Y., Wang, H., Liang, X et al. Pathological and prognostic significance of hypoxia-inducible factor 1alpha expression in epithelial ovarian cancer: a meta-analysis. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 2014;35, 8149?8159, doi:10.1007/s13277-014-2059-x,
  19. Zheng SS, Chen XH, Yin X et al. Prognostic significance of HIF-1alpha expression in hepatocellular carcinoma: a meta-analysis. PLoS One. (e65753):2013;1?7.
  20. Shimogai R, Kigawa J, Itamochi H, et al. Expression of hypoxiainducible factor 1alpha gene affects the outcome in patients with ovarian cancer. Int J Gynecol Cancer 2008;18:499?505.
  21. Nakai H,WatanabeY, Ueda H, Hoshiai H.. Hypoxia inducible factor 1- alpha expression as a factor predictive of efficacy of taxane/platinum chemotherapy in advanced primary epithelial ovarian cancer. Cancer Lett 2007;251:164?7.
  22. Birner P, Schindl M, Obermair A et al.. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000; 60:4693?6.
  23. Ruscito I, Gasparri ML, Marchetti C, et al.. Cediranib in ovarian cancer: state of the art and future perspectives. Tumour Biol 2016; 37: 2833?2839.
  24. Ting Liu, Le Zhao, Huilian Hou et al. Ginsenoside 20(S)-Rg3 suppresses ovarian cancer migration via hypoxia-inducible factor 1 alpha and nuclear factor-kappa B signals Tumor Biology: 2017;1? 10
  25. Zhang H, Qian DZ, Tan YS, et al.. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A 2008;105(50): 19579?19586.
  26. Zagzag D, Nomura M, Friedlander DR, et al.. Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion. J Cell Physiol 2003;196(2): 394?402.
  27. Kar S, Fan J, Smith MJ et al: Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J 2003, 22:70?77.
  28. Tanaka S1, Nohara T, Iwamoto M, et al.: Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer. Cancer Chemother Pharmacol 2009, 64:341?6.
  29. Wu H, Huang M, Lu M et al.Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity ofgastric cancer to paclitaxel. Cancer Chemother Pharmacol. 2013 May; 71(5):1159-71. doi: 10.1007/s00280-013-2108-y.
  30. Wang Q & Wang N & Shao G et al. Relationship Between Gastric Cancer Tau Protein Expression and Paclitaxel Sensitivity Pathol. Oncol. Res. (2013) 19:429?435
  31. Abd elaziz L, Younis S and Abd el hak M Microtubule associated protein tau as a marker of response to taxene based chemotherapy in primary epithelial ovarian cancer Life Science Journal 2014;11(12)
  32. Steffensen KD, Smoter M, Waldstr?m M, et al.,: Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression. Int J Oncol. 2014 May; 44(5):1736- 44.
  33. Shao YY, Kuo KT, Hu FC, et al. Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin. Jpn J Clin Oncol. 2010; 40:286?293. doi: 10.1093/jjco/hyp184.

[Mouhamed A. Fouad, Mona Saeed Mohamed, Rham Z. Ahmed, Basant Sh El Shafaay and Entsar R Mahdy. (2018); PREDICTIVE AND PROGNOSTIC VALUES OF HYPOXIA-INDUCIBLE FACTOR (HIF)-1Α AND TAU-PROTEIN EXPRESSION IN SEROUS OVARIAN CANCER (SOC) PATIENTS TREATED WITH CHEMOTHERAPY. Int. J. of Adv. Res. 6 (Jul). 152-166] (ISSN 2320-5407). www.journalijar.com

Mouhamed A. Fouad
Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

DOI:

Article DOI: 10.21474/IJAR01/7347      
DOI URL: http://dx.doi.org/10.21474/IJAR01/7347

Download Full Paper

Download PDF No. of Downloads: 5 | No. of Views: 41